Digipath
CHM Cannabis
Home > Boards > US Listed > Biotechs >

Bio-Path Holdings Inc. (BPTH)

BPTH RSS Feed
Add BPTH Price Alert      Hide Sticky   Hide Intro
Moderator: SJSTOCKSHARK
Search This Board: 
Last Post: 12/11/2018 11:27:00 AM - Followers: 56 - Board type: Free - Posts Today: 0

Bio-path Holdings Inc.

WARNING: 

A REVERSE SPLIT HAS OCCURRED AND A SECOND 1-20 REVERSE SPLIT IS PROPOSED!

Company description:

Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001, known as Prexigebersen has completed a partial phase II combination trial (with LDAC). The interim results demonstrated 47% of the patients showed early anti-leukemic activity. The company is in the process of amending the dosing protocols for the combination trial and adding a Decitabine cohort.


http://www.biopathholdings.com/wp-content/uploads/2018/04/BPTH_Interim_Phase_2_AML_Data_Release.pdf 
 

The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Several years ago Gilead attempted to produce viable antisense drugs unsuccessfully, because of high toxicity caused by their cationic (positively charged) liposome delivery system. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive. Will the company apply for FDA acclerated status as interim testing is complete on 17 evaluable patients?

A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson but we are awaiting the FDA website comfirmation of same.

Patent protection for manufacturing their neutral lipid delivery system has been granted.

 
Bio-Path Holdings may also begin in 2018 phase 1 testing of their antisense drug Prexigebersen on certain types of uterine cancer. An IND using Prexigebersen for treatment resistent breast cancer may also occur.  Additionally, BPTH is initiating the development of a second drug BP1002 targeting Bcl-2 for Follicular Lymphoma. An IND for BP1002 is projected to occur in 2018. The third drug BP1003 which targets the Stat-3 protein, is expected to begin IND-enabling studies with a goal to enter first in-human trials in 2019 for treatment of pancreatic tumors.

The company has entered into a sponsored research agreement with the University of Texas Southwestern Medical Center to evaluate BPTH's pipeline for efficacy in down-regulating the immune response using systemic lupus erythematosus (SLE) as a model. Bio-Path has entered into a sponsored research agreement with Thomas Jefferson University to investigate DNAbilize™ antisense DNA technology for the development of a brain cancer immunotherapy that works by activating the patient’s own immune system to fight their cancer. Also, BPTH has entered into a sponsored research agreement with MD Anderson to evaluate the ability of its pipeline to modulate pancreatic cancer.


http://www.biopathholdings.com


While antisense drugs fell out of favor following Gilead's failed efforts there was some renewed interest. Ionis established partnerships with Biogen Idec and GlaxoSmithKline for their antisense technology. At the present BPTH has no partnerships with drug manufacturers but if BPTH's delivery system and drugs continue to show promise partnerships are expected.

This link to the company website describes their delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 1+ million in cash.

 
Bio-Path Holdings does not manufacture their drugs but uses contractors, hence the need for partners.
 
BPTH is presently traded on the NASDAQ.

Here are links to articles on their drug technology:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/wp-content/uploads/2017/06/Published-Article-Evolution-of-Antisense-in-Oncology.pdf

http://www.biopathholdings.com/wp-content/uploads/2018/03/BPTH_Lancet_20180329.pdf

Analyst coverage:

Stonegate Capital target $11-14

http://stonegateinc.com/reports/BPTH_Update_June_2018.pdf


 
 
 
 
Digipath
CHM Cannabis
BPTH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#4192   IMO the only way to affect real change SJSTOCKSHARK 12/11/18 11:27:00 AM
#4191   The newly issued shares from the last round SJSTOCKSHARK 12/10/18 03:05:44 PM
#4190   Wish you the best Cautious! I think you too simple 12/08/18 12:32:53 PM
#4189   Well, I finally sold all my shares. cautious optimist 12/07/18 07:04:18 PM
#4188   A final point. BPTH believes a 1 – SJSTOCKSHARK 12/06/18 07:21:23 PM
#4187   Simple, To buy the company a premium would SJSTOCKSHARK 12/06/18 06:45:37 PM
#4186   This is what I don’t understand. Why 11m too simple 12/06/18 11:42:33 AM
#4185   This is what I don’t understand. Why 11m too simple 12/06/18 11:42:22 AM
#4184   Who would want BPTH? SJSTOCKSHARK 12/06/18 10:27:22 AM
#4183   Question for those that know more about this too simple 12/06/18 08:02:17 AM
#4182   The latest poster presentation looks to me like blairsoldman 12/04/18 04:52:43 PM
#4181   Crai, Good point, plus the small amount of SJSTOCKSHARK 12/03/18 05:19:55 PM
#4180   By the time the shorts are done with craiviolin 12/03/18 04:14:11 PM
#4179   The board needs to do to PN what Runninonempty 12/03/18 02:55:16 PM
#4178   I have to agree with you SJ. They too simple 12/03/18 12:49:09 PM
#4177   It is time for harsh rebuke of PN SJSTOCKSHARK 12/03/18 11:19:54 AM
#4176   I voted no on everything but the auditor. SJSTOCKSHARK 12/02/18 06:00:37 PM
#4175   Any opinions on how we should vote? blairsoldman 12/02/18 04:32:57 PM
#4174   Runnin, We will see. IMO The purpose of SJSTOCKSHARK 12/01/18 06:16:28 PM
#4173   SJ, BPTH won’t have the reverse split til Runninonempty 11/30/18 03:49:24 PM
#4172   Crai, Here is the reason for the sell SJSTOCKSHARK 11/30/18 11:36:32 AM
#4171   WHAT A SELL OFF TODAY OVER 26%!!! craiviolin 11/29/18 06:44:09 PM
#4170   Is the market telling us no new news SJSTOCKSHARK 11/29/18 01:06:05 PM
#4169   Wasatch front scam tyroneweaver 11/22/18 01:08:50 AM
#4168   To quote Sergeant Schultz “I know nothing” SJSTOCKSHARK 11/20/18 09:18:20 PM
#4167   What are you hearing SJ? Something is obviously Runninonempty 11/20/18 11:20:45 AM
#4166   What a travesty.....more of the same. I actually craiviolin 11/15/18 05:28:10 PM
#4165   Any ideas on how to vote the end Mt Bobster 11/15/18 11:41:03 AM
#4164   3rd Q conference call. SJSTOCKSHARK 11/15/18 11:21:25 AM
#4163   HOUSTON, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Bio-Path SJSTOCKSHARK 11/09/18 10:49:57 AM
#4162   PN claims he wants long term investors. He SJSTOCKSHARK 11/03/18 01:28:10 PM
#4161   Pardon my ignorance, but how does a RRS blairsoldman 11/03/18 10:16:09 AM
#4160   Runin, Does that make you a buyer of SJSTOCKSHARK 11/02/18 07:38:15 PM
#4159   So are we surprised by that news? Of Runninonempty 11/02/18 05:50:46 PM
#4158   Simple, Yes. SJSTOCKSHARK 11/02/18 04:42:24 PM
#4157   Well said SJS ! I have been wondering too simple 11/02/18 01:59:39 PM
#4156   Rather than messing around with reverse splits PN SJSTOCKSHARK 11/02/18 01:13:58 PM
#4155   Crai, Agreed! This stock is trading at below SJSTOCKSHARK 11/02/18 12:09:27 PM
#4154   Yesterday I sent an email to PN and craiviolin 11/01/18 05:42:56 PM
#4153   PN finally pays a price for his management SJSTOCKSHARK 11/01/18 12:37:18 PM
#4152   The timing of the "poster" presentation is right SJSTOCKSHARK 11/01/18 10:22:55 AM
#4151   $BPTH news Dec 1-4 Dr. Maro Ohanian will r1aviator 11/01/18 09:14:26 AM
#4150   Blair, Your point is well taken. Simple malfeasance SJSTOCKSHARK 10/31/18 10:05:34 AM
#4149   Stupidity and ineptitude are not culpable offences are blairsoldman 10/31/18 12:03:35 AM
#4148   Runnin, In my opinion no one will provide SJSTOCKSHARK 10/30/18 05:04:45 PM
#4147   Reverse splits are not BPTH’s biggest concern at Runninonempty 10/30/18 03:27:20 PM
#4146   Blair, Ignorant you are not, but imo PN SJSTOCKSHARK 10/30/18 12:01:03 PM
#4145   Musing on this in my ignorant way it blairsoldman 10/30/18 11:40:22 AM
#4144   Crai,Purchase by the BOD? How? Who on the SJSTOCKSHARK 10/29/18 10:45:19 PM
#4143   Has it occurred to anyone the possibility of craiviolin 10/29/18 05:50:38 PM
PostSubject